e authors of the guidelines [1] thank Drs. Rudolph and Fischer (InfectoPharm) for their comments [2] and would like to respond as follows: 1. It is correct that the administration of 2 ml of a 1-mg/ml adrenaline solution in inhaled form, as stated in Tables 6 and 7 , does not conform to the drug approval for ampules available on the market. e authors regret that they did not make explicit reference to this "o -label" status. Possible side e ects due to sulphite content should be of minor importance in an emergency setting. However, the alternative mentioned, i.e., inhaling with InfectoKrupp Inhal®, is similarly not approved for use in anaphylaxis.
2.
While it is also correct that an adrenaline solution is available for use in a nebulizer, this preparation is not -as mentioned above -approved for the treatment of anaphylaxis. e above-mentioned study by Breuer et al. [3] was commissioned by the manufacturer as a preclinical pilot study in eight healthy adults that used a nebulizer system of this kind. Said study had serum concentration as its sole endpoint and did not investigate the clinical e ect of adrenaline. us, it is not possible to draw any valid conclusions on the efcacy of this method in the treatment of anaphylaxis. Furthermore, the preparation appears to be di cult to handle in an emergency setting to the extent that, following intense discussion, the guideline group decided against recommending it for this indication. In summary, it is correct that the o -label use of medicinal products should be explicitly mentioned in guidelines. is omission is hereby recti ed. We express our thanks to Drs. Rudolph and Fischer for drawing our attention to this point. e recommendation regarding the described treatment procedure remains otherwise unchanged. 
